Trial Profile

Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 20 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gilteritinib (Primary) ; Cytarabine; Daunorubicin; Midostaurin
Indications Acute myeloid leukaemia
Focus Therapeutic Use

Most Recent Events

20 Apr 2051 The description part in NCT mentions- "a review of the effectiveness of gliteritinib compared to midostaurin will be done. If gilteritinib is not as effective as midostaurin, the study may be stopped." thus Midostaurin appears to be a comparator, hence I have not marked it primary.
15 Jun 2025 Planned End Date changed from 1 Jun 2025 to 1 Dec 2026.
28 Feb 2025 Planned End Date changed from 1 Dec 2024 to 1 Jun 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com